百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688235 百济神州

已收盘 11-22 15:00:01

{"stockData":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":166.43,"timestamp":1732258801000,"preClose":169.28,"halted":0,"volume":2300938,"delay":0,"floatShares":114999999,"shares":1381000000,"eps":-4.7238,"marketStatus":"已收盘","marketStatusCode":5,"change":-2.85,"latestTime":"11-22 15:00:01","open":167.79,"high":172.5,"low":166.08,"amount":388000000,"amplitude":0.0379,"askPrice":166.63,"askSize":2,"bidPrice":166.43,"bidSize":6,"shortable":0,"etf":0,"ttmEps":-4.7238,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":169.28,"symbolType":"stock_kcb","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":186.21,"lowLimit":152.35,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1381200531,"pbRate":9.51,"roa":"--","roe":"--","epsLYR":-4.95,"committee":0.301205,"marketValue":229873000000,"floatMarketCap":19149000000,"peRate":-35.232227,"changeRate":-0.0168,"turnoverRate":0.02,"status":1,"afterMarket":{"amount":0,"volume":0,"close":166.43,"buyVolume":0,"sellVolume":0,"time":1732260839464,"indexStatus":"已收盘 11-22 15:30:00","preClose":169.28}},"requestUrl":"/m/hq/s/688235","defaultTab":"news","newsList":[{"id":"2485287927","title":"百济神州-U11月22日主力资金流入2160万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2485287927","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485287927?lang=zh_cn&edition=full","pubTime":"2024-11-22 15:20","pubTimestamp":1732260052,"startTime":"0","endTime":"0","summary":"11月22日, 百济神州-U股价跌1.68%，报收166.43元，成交金额3.88亿元，换手率2.00%，振幅3.79%，量比0.73。百济神州-U今日主力资金净流入2160万元，连续3日净流入，上一交易日主力净流入2497万元，今日环比减少13.50%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为16.67%，平均涨幅为1.86%。该股近5个交易日上涨0.67%，主力资金累计净流入517万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出8935万元，其中净流出天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122154143a24d50ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122154143a24d50ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2485928956","title":"百济神州前三季度再亏36亿元，现金流持续告负、用14.67亿元超募资金补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2485928956","media":"消费日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485928956?lang=zh_cn&edition=full","pubTime":"2024-11-22 14:42","pubTimestamp":1732257720,"startTime":"0","endTime":"0","summary":"据梳理，这是百济神州2022年来第三次使用超募资金补流，三次资金累计达14.67亿元。由此可知百济神州七年共亏损约541.8亿元。今年前三季度百济神州的“三费”均以两位数的同比增速在增加，“三费”合计达到196.66亿元。百济神州今年前三季度营业收入为191.36亿元，同比增长48.6%；归属于上市公司股东的净利润为-36.87亿元。资料显示，百济神州2021年登陆科创板时通过IPO募资221.6亿元，扣除发行费用后的募资净额为216.3亿元，此次发行的超募资金约为16.30亿","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122144739a24d2f65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122144739a24d2f65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688235","BGNE","06160"],"gpt_icon":0},{"id":"2485864544","title":"港股异动 | 百济神州(06160)盘中涨近3% PRMT5抑制剂国内获批临床 明年将来迎密集催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2485864544","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485864544?lang=zh_cn&edition=full","pubTime":"2024-11-21 10:56","pubTimestamp":1732157809,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州盘中涨近3%，截至发稿，涨2.29%，报120.5港元，成交额1.4亿港元。消息面上，11月19日，据CDE网站显示，百济神州申报的1类新药BGB-58067片获得临床试验默示许可，拟开发治疗晚期实体瘤患者。根据百济神州公开资料，BGB-58067是一款PRMT5抑制剂，为百济神州未来的核心项目之一。根据CDE官网查询，这是该产品首次在中国获批临床。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0588546209.SGD","BK0239","BK1161","BK4504","BK4535","BK1583","BK4505","688235","LU1969619763.USD","BGNE","BK1588","06160","BK4139","BK4526","BK4585","BK4548","LU2328871848.SGD","BK1500","BK4588","LU0307460666.USD"],"gpt_icon":0},{"id":"2485102515","title":"百济神州11月20日获南向资金加仓30.42万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485102515","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485102515?lang=zh_cn&edition=full","pubTime":"2024-11-21 09:30","pubTimestamp":1732152616,"startTime":"0","endTime":"0","summary":"11月20日, 南向资金增持百济神州30.42万股。截止当日收盘，港股通共持有百济神州6307.20万股，占流通股4.54%。百济神州近5个交易日下跌1.01%，港股通累计增持329.09万股；近20个交易日下跌11.96%，港股通累计增持697.73万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121093243a249eddc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121093243a249eddc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BGNE","BK0239","06160"],"gpt_icon":0},{"id":"2485170656","title":"百济神州：PRMT5抑制剂获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2485170656","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485170656?lang=zh_cn&edition=full","pubTime":"2024-11-21 07:01","pubTimestamp":1732143702,"startTime":"0","endTime":"0","summary":"据不完全统计，当前全球范围内已有10多款PRMT5抑制剂进入到临床试验阶段。根据百济神州公开资料介绍，该公司研发的BGB-58067为第二代MTA协同PRMT5抑制剂，可选择性杀伤MTAP缺失肿瘤细胞，同时避免影响正常血液细胞。据百济神州公开资料介绍，该公司将在2024年推动10个新分子进入临床试验，包括泛KRAS抑制剂、MTA协同PRMT5抑制剂、EGFR降解剂、CDK2抑制剂、ADC和双特异性免疫细胞衔接器等。本次PRMT5抑制剂获批临床，意味着该产品的研发进程迎来重要进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121070236a2499c2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121070236a2499c2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BGNE","BK0239","06160"],"gpt_icon":0},{"id":"2484411716","title":"百济神州盘中异动 早盘股价大涨5.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484411716","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484411716?lang=zh_cn&edition=full","pubTime":"2024-11-20 22:34","pubTimestamp":1732113252,"startTime":"0","endTime":"0","summary":"北京时间2024年11月20日22时34分，百济神州股票出现异动，股价急速拉升5.70%。截至发稿，该股报198.48美元/股，成交量2.0079万股，换手率0.02%，振幅2.18%。机构评级方面，在所有33家参与评级的机构中，91%的券商给予买入建议，9%的券商给予持有建议，无券商给予卖出建议。百济神州股票所在的生物技术行业中，整体涨幅为0.33%。该信息摘要如下：东吴证券 研报指出， 百济神州 -UQ3销售收入快速增长，经营性现金流转正。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120223412a248c2fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120223412a248c2fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BGNE","688235","BK4526","BK4505","BK4588","BK4504","BK4535","BK4139","BK4548","BK4585"],"gpt_icon":0},{"id":"2484164960","title":"泽布替尼仿制药不得在2037年之前销售，百济神州与MSN达成专利和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2484164960","media":"医药魔方Info","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484164960?lang=zh_cn&edition=full","pubTime":"2024-11-20 17:05","pubTimestamp":1732093511,"startTime":"0","endTime":"0","summary":"11月19日， 百济神州 宣布已与MSN Pharmaceuticals和MSN Laboratories Private公司达成了和解协议，解决了与MSN在美国提交的Brukinsa 仿制药 注册申请相关的专利诉讼问题。根据协议条款，MSN将无法在2037年6月15日之前销售Brukinsa的仿制药，但在某些惯例情况下，该日期可能会提前或延后。MSN在诉讼中并未对Brukinsa的药物组合专利提出异议，该专利将于2034年4月到期。此前，百济神州与诺华子公司Sandoz已联合提交了一份协议，以撤销针对Sandoz提交的ANDA而提起的专利诉讼。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120170922abd188c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120170922abd188c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BGNE","BK0239","06160"],"gpt_icon":0},{"id":"2484138143","title":"百济神州(06160)上涨5.04%，报118.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484138143","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484138143?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:11","pubTimestamp":1732068696,"startTime":"0","endTime":"0","summary":"11月20日，百济神州(06160)盘中上涨5.04%，截至10:11，报118.8元/股，成交7120.85万元。百济神州有限公司是一家专注于开发和商业化用于治疗癌症的创新型分子靶向和肿瘤免疫治疗药物的生物技术公司。公司拥有包括六种内部开发的临床阶段候选药物和五种获得授权许可的药物在内的广泛产品组合，以及超过1300名员工的全球团队。截至2024年三季报，百济神州营业总收入187.97亿元、净利润-34.54亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/20101145475695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0307460666.USD","BGNE","LU0588546209.SGD","BK1583","BK4588","BK4505","BK4139","BK1588","LU2328871848.SGD","688235","LU1969619763.USD","BK1161","BK0239","BK4548","BK4535","BK4585","BK4504","BK4526","06160","BK1500"],"gpt_icon":0},{"id":"2484138240","title":"百济神州盘中异动 股价大涨5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484138240","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484138240?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:11","pubTimestamp":1732068689,"startTime":"0","endTime":"0","summary":"2024年11月20日早盘10时11分，百济神州股票出现波动，股价急速拉升5.13%。截至发稿，该股报118.900港元/股，成交量59.21万股，换手率0.05%，振幅6.10%。机构评级方面，在所有32家参与评级的机构中，91%的券商给予买入建议，9%的券商给予持有建议，无券商给予卖出建议。百济神州股票所在的生物技术行业中，整体涨幅为1.24%。该信息摘要如下：东吴证券 研报指出， 百济神州 -UQ3销售收入快速增长，经营性现金流转正。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120101129a2473c73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120101129a2473c73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","BK1161","688235","LU1969619763.USD","LU0588546209.SGD","BK1500","BK1583","06160","LU0307460666.USD","BK1588"],"gpt_icon":0},{"id":"2484338771","title":"百济神州-U涨5%获主力加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2484338771","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484338771?lang=zh_cn&edition=full","pubTime":"2024-11-20 09:58","pubTimestamp":1732067931,"startTime":"0","endTime":"0","summary":"11月20日，百济神州-U股价大幅上涨，截至09点58分，百济神州-U上涨5.06%，报164.56元/股，成交2.17亿元，换手率1.16%，振幅5.46%。资金动向截止发稿，百济神州-U获得主力净流入1292万元，其中超大单流入904万元，大单流入388万元。主营业务及业绩百济神州-U公司主营业务为研究、开发、生产以及商业化创新型药物。最新财报显示，今年三季报，百济神州-U实现营业收入191.36亿元，同比增长48.63%，净利润为-36.87亿元，同比增长4.94%，基本每股收益为-2.71元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120095911abd0ab65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120095911abd0ab65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239"],"gpt_icon":0},{"id":"2484194184","title":"BUZZ-Labcorp 下跌；任职十年之久的首席财务官将退休","url":"https://stock-news.laohu8.com/highlight/detail?id=2484194184","media":"路透中文","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484194184?lang=zh_cn&edition=full","pubTime":"2024-11-19 21:23","pubTimestamp":1732022620,"startTime":"0","endTime":"0","summary":"BUZZ-Labcorp 下跌；任职十年之久的首席财务官将退休11月19日 -  ** 实验室服务提供商Labcorp控股公司LH.N股价盘前下跌1.7%，至234.49美元 ** 该公司表示，Julia Wang将接替Glenn Eisenberg担任首席财务官，12月2日生效，因为现任首席财务官在担任该职位十多年后将退休 ** Wang最近在生物技术公司BeiGene担任首席财务官，此前曾在Alexion制药公司和强生公司任职。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nL4T3MQ16B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","IE00BJJMRZ35.SGD","LU1244550221.USD","LU1196500208.SGD","LU0640476718.USD","LU1894683348.USD","IE00B3PB1722.GBP","LU1162221912.USD","LU1778281490.HKD","BK4588","LU0345769128.USD","LU1894683264.USD","BK0239","LU1935042991.SGD","BK4532","IE00BGHQF631.EUR","BK4592","LU1244550494.USD","LU0234572021.USD","LU1585245621.USD","BK4196","LU1506573853.SGD","JNJ","IE00B42XCP33.USD","LU1732799900.SGD","LU2089984988.USD","IE00B2B36J28.USD","LU0234570918.USD","LU1914381329.SGD","IE00BJT1NW94.SGD","LU1032466523.USD","688235","LU1066051225.USD","LU0122379950.USD","LU2347655156.SGD","LU0345770308.USD","LU1221951129.SGD","LU1244550577.SGD","SG9999002232.USD","IE0034235303.USD","LU1066053197.SGD","LH","LU0466842654.USD","LU0006061336.USD","IE000M9KFDE8.USD","LU1280957306.USD","IE0002270589.USD","LU0098860793.USD","IE00B19Z3581.USD","LU1066051811.HKD"],"gpt_icon":0},{"id":"2484134179","title":"百济神州(06160)授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2484134179","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484134179?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:01","pubTimestamp":1732010498,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)公布，于2024年11月14 日，董事会薪酬委员会根据2016期权及激励计划的条款向3名承授人授出可认购合共3,628股美国存托股份的购股权并向147名承授人授出涉及合共36,689 股美国存托股份的受限制股份单位。购股权行使价为每股美国存托股份201.28美元(约每股普通股120.46港元)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4505","BK4526","06160","BK4585","LU0588546209.SGD","BK1500","LU1969619763.USD","BK1583","BK0239","BK4548","BK4588","BK4504","BK1588","688235","BK1161","LU2328871848.SGD","BGNE","BK4139","LU0307460666.USD","BK4535"],"gpt_icon":0},{"id":"2484930963","title":"百济神州11月18日获南向资金加仓93.55万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484930963","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484930963?lang=zh_cn&edition=full","pubTime":"2024-11-19 09:30","pubTimestamp":1731979817,"startTime":"0","endTime":"0","summary":"11月18日, 南向资金增持百济神州93.55万股。截止当日收盘，港股通共持有百济神州6234.40万股，占流通股4.49%。百济神州近5个交易日下跌10.46%，港股通累计增持294.31万股；近20个交易日下跌14.95%，港股通累计增持744.48万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119093315a2445030&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119093315a2445030&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4535","688235","BK4504","BGNE","BK4588","06160","BK4139","BK4505","BK4526","BK4548"],"gpt_icon":0},{"id":"2484949934","title":"百济神州（688235）11月18日主力资金净卖出6032.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484949934","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484949934?lang=zh_cn&edition=full","pubTime":"2024-11-19 08:26","pubTimestamp":1731976002,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月18日收盘，百济神州报收于156.21元，下跌5.51%，换手率3.45%，成交量3.97万手，成交额6.34亿元。近5日资金流向一览见下表：百济神州融资融券信息显示，融资方面，当日融资买入4279.99万元，融资偿还6022.09万元，融资净偿还1742.1万元。百济神州主营业务：研究、开发、生产以及商业化创新型药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111900007237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1500","LU0588546209.SGD","BK1588","LU2328871848.SGD","BK1583","06160","LU1969619763.USD","688235","BK1161","LU0307460666.USD","BK0239"],"gpt_icon":0},{"id":"2484564742","title":"一哥的业绩，投资人不买账","url":"https://stock-news.laohu8.com/highlight/detail?id=2484564742","media":"并购菁英汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484564742?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:03","pubTimestamp":1731924185,"startTime":"0","endTime":"0","summary":"按理说，百济神州拳头产品取得强势的增长且公司非GAAP净利润连续第二个季度实现盈利的背景下，公司股价并未像今年二季度业绩公布前后实现市值的显著提升，相反资金却选择了短期内对其进行抛售。显然，百济神州2024Q3费用控制层面让投资者认为有不及预期的地方。尽管百济神州作为海外PD-1市场的后发者，但获批适应症患者数量众多，叠加近日FDA限制已上市部分PD-1在胃癌适应症上的使用，替雷利珠单抗存在一定差异化优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118183602abcc4675&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118183602abcc4675&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BK4087","BK4526","688235","BK4504","LU0053666078.USD","BK4535","BK4505","BK4548","BK4107","BK4585","L","06160","CHMP","BGNE"],"gpt_icon":0},{"id":"2484617046","title":"11月18日百济神州-U跌5.51%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484617046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484617046?lang=zh_cn&edition=full","pubTime":"2024-11-18 16:12","pubTimestamp":1731917526,"startTime":"0","endTime":"0","summary":"证券之星消息，11月18日百济神州-U跌5.51%，收盘报156.21元，换手率3.45%，成交量3.97万手，成交额6.34亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共128家，其中持有数量最多的公募基金为万家行业优选LOF。万家行业优选LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800019693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","160916","BK1588","06160","LU0588546209.SGD","LU2328871848.SGD","688235","BK1500","LU1969619763.USD","BK0239","BK1161","LU0307460666.USD"],"gpt_icon":0},{"id":"2484857612","title":"研报掘金丨东吴证券：百济神州成长确定性较高，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2484857612","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484857612?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:47","pubTimestamp":1731916029,"startTime":"0","endTime":"0","summary":"格隆汇11月18日｜东吴证券研报指出，百济神州-UQ3销售收入快速增长，经营性现金流转正。Q3 总收入达10.02亿美元，2024Q1-Q3 收入分别为7.5/9.3/10.0亿美元，欧美市场贡献超76%。截至前三季度，GAAP净亏损1.21亿美元，业绩符合的预期。考虑到公司核心产品销售额持续高速增长，维持公司2024/2025/2026 年营业收入为255.3亿元、340.6亿元和423.8亿元的预测。公司催化剂不断兑现，海外市场进一步打开，成长确定性较高，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118154717abcbb81f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118154717abcbb81f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","601555"],"gpt_icon":0},{"id":"2484614360","title":"《大行》交银国际升百济神州(06160.HK)目标价至159元  催化剂即将密集落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2484614360","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484614360?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:33","pubTimestamp":1731915180,"startTime":"0","endTime":"0","summary":"交银国际发表报告指，百济神州第三季产品销售放量趋势不改，泽布替尼核心适应症新患份额持续扩大：公司总收入按年增长28.2%至10.02亿美元。经调整non-GAAP经营利润为6,563万美元，连续两个季度实现non-GAAP经营利润转正。该行上调百济神州H股目标价至159港元。沽空资料截至 2024-11-18 12:25。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20181116161836565_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20181116161836565_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1397482/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["688235","06160"],"gpt_icon":0},{"id":"2484614005","title":"百济神州-U11月18日遭主力抛售6308万元 环比增加1555.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484614005","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484614005?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:21","pubTimestamp":1731914473,"startTime":"0","endTime":"0","summary":"11月18日, 百济神州-U股价跌5.51%，报收156.21元，成交金额6.34亿元，换手率3.45%，振幅7.71%，量比1.06。百济神州-U今日主力资金净流出6308万元，连续5日净流出，上一交易日主力净流出381万元，今日环比增加1555.64%。该股近5个交易日下跌16.43%，主力资金累计净流出2.18亿元；近20日主力资金累计净流出2.34亿元，其中净流出天数为13日。净流出前三个股分别为恒瑞医药、常山药业、百济神州-U。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118154548abcbb696&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118154548abcbb696&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2484861488","title":"《大行》招银国际降百济神州(BGNE.US)目标价至276.02美元  non-GAAP利润持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2484861488","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484861488?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:06","pubTimestamp":1731913560,"startTime":"0","endTime":"0","summary":"招银国际发表报告指出，百济神州第三季产品销售9.93亿美元，按季升8%，按年升67%。季内，百济神州从营运中产生1.88亿美元的正向现金流入。凭借其强劲的销售势头及不断改善的经营利润率，该行料百济神州将于2025财年实现收支平衡。此外，该行维持对百济神州美股的“买入”评级，目标价由288.93美元下调至276.02美元，认为公司仍是其首选。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240724105052352_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240724105052352_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1397479/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06160","688235"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-12-15","address":"MourantGovernanceServices（Cayman）Limited,94SolarisAvenue,CamanaBay,POBox1348,GrandCaymanKY1-1108,CaymanIslands","stockEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":-0.0526},{"period":"3month","weight":0.1438},{"period":"6month","weight":0.3936},{"period":"1year","weight":0.1677},{"period":"ytd","weight":0.2175}],"companyName":"百济神州有限公司","boardCode":"AI0027","perCapita":"3438股","boardName":"医药制造业","registeredCapital":"138120万元","compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.1808},{"period":"6month","weight":0.0911},{"period":"1year","weight":0.1074},{"period":"ytd","weight":0.1329}],"survey":"　　百济神州有限公司是一家全球性、商业阶段的生物科技公司，专注于研究、开发、生产以及商业化创新型药物，主要产品百悦泽（（BRUKINSA），BTK抑制剂）、百泽安（抗PD-1单抗）、帕米帕利。","serverTime":1732281118669,"listedPrice":192.6,"stockholders":"33458人(较上一季度减少11.03%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,688235,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}